Histavert 24 Tablet contains Betahistine 24 mg, a histamine analog used primarily in the management of vertigo associated with Ménière’s disease and other vestibular disorders. Betahistine acts by improving microcirculation in the inner ear, thereby reducing endolymphatic pressure and alleviating symptoms such as dizziness, tinnitus, and hearing loss. The drug functions as a histamine H1 receptor agonist and H3 receptor antagonist, which enhances histaminergic neurotransmission and promotes vasodilation in the inner ear vasculature. Histavert 24 is indicated for patients experiencing recurrent vertigo attacks and imbalance due to vestibular dysfunction. It is generally well tolerated, with common adverse effects including mild gastrointestinal disturbances such as nausea and dyspepsia. Betahistine should be used with caution in patients with a history of peptic ulcers or asthma. The usual dosage involves oral administration of one tablet twice daily, but dosing may be adjusted based on clinical response and tolerability. Histavert 24 is contraindicated in patients with pheochromocytoma. It is important to monitor patients for any hypersensitivity reactions and to advise them to report any persistent side effects. This medication should be used under medical supervision to ensure optimal therapeutic outcomes.